Search Images Play YouTube Gmail Drive Calendar Translate More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberWO1992017211 A1
Publication typeApplication
Application numberPCT/US1992/002911
Publication date15 Oct 1992
Filing date3 Apr 1992
Priority date5 Apr 1991
Also published asCA2107789A1, EP0578776A1, EP0578776A4
Publication numberPCT/1992/2911, PCT/US/1992/002911, PCT/US/1992/02911, PCT/US/92/002911, PCT/US/92/02911, PCT/US1992/002911, PCT/US1992/02911, PCT/US1992002911, PCT/US199202911, PCT/US92/002911, PCT/US92/02911, PCT/US92002911, PCT/US9202911, WO 1992/017211 A1, WO 1992017211 A1, WO 1992017211A1, WO 9217211 A1, WO 9217211A1, WO-A1-1992017211, WO-A1-9217211, WO1992/017211A1, WO1992017211 A1, WO1992017211A1, WO9217211 A1, WO9217211A1
InventorsLei Han, Thomas E Wagner
ApplicantEdison Animal Biotech Center
Export CitationBiBTeX, EndNote, RefMan
External Links: Patentscope, Espacenet
Inhibition d'un retrovirus a l'aide d'acides nucleiques non codants s'hybridant sur des sequences d'encapsidation
WO 1992017211 A1
Abstract
Cette invention concerne des molécules d'acide nucléique non codantes qui ne s'hybrident pratiquement que sur la séquence d'encapsidation d'un retrovirus et qui inhibent par conséquent l'encapsidation de l'ARN du génome du rétrovirus. Les molecules non codantes peuvent être de l'ADN, de l'ARN, ou des analogues de ces derniers. On peut administrer les molécules non codantes sous forme médicamenteuse ou bien l'individu devant être protégé peut être soumis à des manipulations génétiques afin d'exprimer un ARN non codant.
Description  available in English
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4757055 *27 Apr 198412 Jul 1988The Johns Hopkins UniversityMethod for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
Non-Patent Citations
Reference
1 *Journal of Virology, Volume 61, No. 5, issued May 1987, BENDER et al., "Evidence that the Packaging Signal of Moloney Murine Leukemia Virus Extends into the gag Region", pages 1639-1646, see the entire document.
2 *Journal of Virology, Volume 61, No. 9, issued September 1987, EMBRETSON et al., "Lack of Competition Results in Efficient Packaging of Heterologous Murine Retroviral RNAs and Reticuloendotheliosis Virus Encapsidation-Minus RNAs by the Reticuloendotheliosis Virus Helper Cell Line", pages 2675-2683, see the entire document.
3 *Journal of Virology, Volume 63, No. 2, issued February 1989, VON RUDEN et al., "Inhibition of Human T-Cell Leukemia Virus Type I Replication in Primary Human T Cells that Express Antisense RNA", pages 677-682, see the entire document.
4 *Journal of Virology, Volume 63, No. 9, issued September 1989, LEVER et al., "Identification of a Sequence Required for Efficient Packaging of Human Immunodeficiency Virus Type 1 RNA into Virions", pages 4085-4087, see the entire document.
5 *Proc. Natl. Acad. Sci. USA, Volume 84, issued August 1987, LEDLEY et al., "Retroviral gene transfer into primary hepatocytes: Implications for genetic therapy of liver-specific functions", pages 5335-5339, see the entire document.
6 *Proc. Natl. Acad. Sci. USA, Volume 85, issued August 1988, GOODSCHILD et al., "Inhibition of Human Immunodeficiency Virus replication by antisense oligodeoxynucleotides", pages 5507-5511, see the entire document.
7 *Science, Volume 240, issued 10 June 1988, JAENISCH, "Transgenic Animals", pages 1468-1474, see the entire document.
8 *See also references of EP0578776A1
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
WO1994020146A1 *28 Feb 199415 Sep 1994Pascale BriandAdenovirus recombinants et leur utilisation en therapie genique pour le traitement des pathologies oculaires
WO1995018854A1 *5 Jan 199513 Jul 1995Gene Shears Pty LtdRibozymes ciblant les produits de recombinaison d'expression de sequences d'encapsidation retrovirales et retrovirus recombines contenant lesdits produits de recombinaison
WO1995027783A1 *5 Apr 199519 Oct 1995Joshi Sukhwal SadnaInhibition de la multiplication du vih-1 dans des cellules de mammiferes
WO1996022368A1 *18 Jan 199625 Jul 1996Gene Shears Pty LtdRibozymes de recombinaison cibles contre des sequences exprimant la capside retrovirale et retrovirus contenant de tels produits recombines
DE4225094A1 *29 Jul 19924 Nov 1993Frank Andreas Harald MeyerMedikament zur gentherapeutischen behandlung von menschen, tieren und pflanzen, insbesondere zur blockierung der virenvermehrung und der tumorgene sowie verfahren zur herstellung des medikaments
EP0594881A1 *28 Oct 19924 May 1994Bayer AgVecteurs d'expression et leur utilisation pour la production de cellules humaines résistantes au HIV pour les applications thérapeutiques
EP0598935A1 *24 Nov 19921 Jun 1994Bayer AgVecteurs d'expression et leur utilisation pour la production de cellules humaines résistantes à HIV pour utilisation thérapeutique
US5583035 *14 Nov 199410 Dec 1996Bayer AktiengesellschaftHIV antisense expression vectors
US5712384 *5 Jan 199427 Jan 1998Gene Shears Pty Ltd.Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US6114167 *21 Sep 19945 Sep 2000Gene Shears Pty., Ltd.Ribozymes targeting the MoMLV PSI packaging sequence and the HIV tat sequence
US64585292 Jun 19951 Oct 2002Aventis Pharma S.A.Infecting quiescent central nervous cells with recombinant adenovirus having marker gene linked to promoter, then detecting expression of marker gene in cells
US734502510 Jul 200218 Mar 2008Johnson & Johnson Research Pty. LimitedEx vivo gene therapy; HIV infection; at least 1.63 x 106 CD34+ hematopoietic cells (per kg of body weight) being transduced with a viral construct which expresses an anti-HIV agent
US777659518 Aug 200617 Aug 2010Johnson & Johnson Research Pty, LimitedMethods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
US799414410 Jul 20029 Aug 2011Johnson & Johnson Research Pty, LimitedProcess for the preparation of a composition of genetically modified hematopoietic progenitor cells
Classifications
International ClassificationA61K31/70, C12N5/10, A61K48/00, A61P31/12, C12N15/85, C12N15/09, A01K67/027, C12N15/48, C12N15/113
Cooperative ClassificationC12N15/8509, A01K67/0275, A01K2227/105, A01K2267/0337, A61K48/00, A01K2217/05, C12N15/1131, A01K2267/02
European ClassificationC12N15/85A, A01K67/027M, C12N15/113A
Legal Events
DateCodeEventDescription
13 Sep 1999WWW
Ref document number: 1992910993
Country of ref document: EP
19 Jan 1994WWP
Ref document number: 1992910993
Country of ref document: EP
5 Oct 1993ENP
Ref country code: CA
Ref document number: 2107789
Kind code of ref document: A
Format of ref document f/p: F
5 Oct 1993WWE
Ref document number: 2107789
Country of ref document: CA
4 Oct 1993WWE
Ref document number: 1992910993
Country of ref document: EP
4 Mar 1993DFPE
15 Oct 1992AL
Kind code of ref document: A1
Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE
15 Oct 1992AK
Kind code of ref document: A1
Designated state(s): AU CA JP KR